edaravone has been researched along with Constipation in 1 studies
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An intravenous (IV) formulation of edaravone has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS)." | 9.69 | Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. ( Aoki, M; Apple, S; Bidani, S; Couratier, P; Genge, A; Hirai, M; Jackson, CE; Kalin, A; Lunetta, C; Pattee, GL; Petri, S; Sakata, T; Salah, A; Selness, D; Sobue, G; Wamil, A; Yoshino, H, 2023) |
| "An intravenous (IV) formulation of edaravone has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS)." | 5.69 | Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. ( Aoki, M; Apple, S; Bidani, S; Couratier, P; Genge, A; Hirai, M; Jackson, CE; Kalin, A; Lunetta, C; Pattee, GL; Petri, S; Sakata, T; Salah, A; Selness, D; Sobue, G; Wamil, A; Yoshino, H, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Genge, A | 2 |
| Pattee, GL | 2 |
| Sobue, G | 2 |
| Aoki, M | 2 |
| Yoshino, H | 2 |
| Couratier, P | 2 |
| Lunetta, C | 2 |
| Petri, S | 2 |
| Selness, D | 2 |
| Bidani, S | 2 |
| Hirai, M | 2 |
| Sakata, T | 2 |
| Salah, A | 2 |
| Apple, S | 2 |
| Wamil, A | 2 |
| Kalin, A | 2 |
| Jackson, CE | 2 |
1 trial available for edaravone and Constipation
| Article | Year |
|---|---|
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male; | 2023 |
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male; | 2023 |
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male; | 2023 |
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male; | 2023 |